ATNM Key Statistics, Chart & Performance
The current stock price of ATNM is 1.59 USD. In the past month the price increased by 13.57%. In the past year, price increased by 32.5%.
ATNM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ATNM
Company Profile
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 37 full-time employees. The company went IPO on 2014-03-26. The firm is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The firm is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
Company Info
ACTINIUM PHARMACEUTICALS INC
100 Park Ave., 23Rd Floor
New York City NEW YORK 10016 US
CEO: Sandesh Seth
Employees: 37
Phone: 16466773870
ACTINIUM PHARMACEUTICALS INC / ATNM FAQ
What does ATNM do?
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 37 full-time employees. The company went IPO on 2014-03-26. The firm is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The firm is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
What is the stock price of ACTINIUM PHARMACEUTICALS INC today?
The current stock price of ATNM is 1.59 USD. The price increased by 0.63% in the last trading session.
What is the dividend status of ACTINIUM PHARMACEUTICALS INC?
ATNM does not pay a dividend.
What is the ChartMill rating of ACTINIUM PHARMACEUTICALS INC stock?
ATNM has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is ATNM stock listed?
ATNM stock is listed on the NYSE Arca exchange.
Can you provide the upcoming earnings date for ACTINIUM PHARMACEUTICALS INC?
ACTINIUM PHARMACEUTICALS INC (ATNM) will report earnings on 2026-03-30, after the market close.
What is the Short Interest ratio of ACTINIUM PHARMACEUTICALS INC (ATNM) stock?
The outstanding short interest for ACTINIUM PHARMACEUTICALS INC (ATNM) is 2.91% of its float.
ATNM Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ATNM. When comparing the yearly performance of all stocks, ATNM is one of the better performing stocks in the market, outperforming 78.99% of all stocks.
ATNM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATNM. While ATNM seems to be doing ok healthwise, there are quite some concerns on its profitability.
ATNM Financial Highlights
Over the last trailing twelve months ATNM reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS increased by 21.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.12% | ||
| ROE | -215.83% | ||
| Debt/Equity | 0 |
ATNM Forecast & Estimates
11 analysts have analysed ATNM and the average price target is 5.1 USD. This implies a price increase of 220.75% is expected in the next year compared to the current price of 1.59.
For the next year, analysts expect an EPS growth of 13.26% and a revenue growth -76.23% for ATNM